Intelligence ยท Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe โ grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring โค24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months โ use filters for patent-cliff planning.
-
US 10351844
Methods and compositions for treating leber congenital amaurosis
granted -
US 10351587
Method of making and using 7ฮฑ, 11ฮฒ-dimethyl-17ฮฒ-hydroxyestr-4-en-3-one 17-undecanoate
granted -
US 10350273
Treatment of hormonal disorders of growth
granted -
US 10350312
Magnetic microstructures for magnetic resonance imaging
granted -
US 10351606
Mutated Salmonella enterica
granted -
US 10342871
Compositions containing nucleosides and manganese and their uses
granted -
US 10342791
Regimens of tafenoquine for prevention of malaria in malaria-naive subjects
granted -
US 10335478
Avirulent, immunogenic flavivirus chimeras
granted -
US 10335460
IL-15 and IL-15Rฮฑ heterodimer dose escalation regimens for treating conditions
granted -
US 10335426
N-acetyl mannosammine as a therapeutic agent
granted -
US 10335423
Inhibition of HIV infection through chemoprophylaxis
granted -
US 10335365
Bladder cancer specific ligand peptides
granted -
US 10335465
Mutant OPAA enzyme with increased catalytic efficiency on organophosphorus compound GP
granted -
US 10329259
Pyrazole derivatives and their use as cannabinoid receptor mediators
granted -
US 10329339
Anti-human papillomavirus 16 E6 T cell receptors
granted -
US 10322099
Process to prepare treprostinil, the active ingredient in remodulinยฎ
granted -
US 10323083
Agents that specifically bind matrilin-3 and their use
granted -
US 10322125
TGF-beta enhancing compositions for cartilage repair and methods related thereto
granted -
US 10322146
Methods of conditioning patients for T cell therapy
granted -
US 10316289
Methods of producing T memory stem cell populations
granted -
US 10314924
RPGR gene therapy for retinitis pigmentosa
granted -
US 10314908
Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
granted -
US 10314900
Lutzomyia longipalpis polypeptides and methods of use
granted -
US 10307477
Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
granted -
US 10307476
Genetically stable live attenuated respiratory syncytial virus vaccine and its production
granted -
US 10308927
Processing of a modified foot-and-mouth disease virus P1 polypeptide by an alternative protease
granted -
US 10307469
Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic acidemia (MMA)
granted -
US 10307423
FBXO3 inhibitors
granted -
US 10307388
Compositions and methods for diagnosis and treatment of inflammation
granted -
US 10308591
Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure
granted -
US 10301621
Multifunctional RNA nanoparticles and methods of use
granted -
US 10301314
Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis
granted -
US 10301377
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
granted -
US 10300123
Synthetic peptide-based marker vaccine and diagnostic system for effective control of porcine reproductive and respiratory syndrome (PRRS)
granted -
US 10300095
AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
granted -
US 10300115
Methods and compositions for modulating immune tolerance
granted -
US 10293005
Use of gram negative species to treat atopic dermatitis
granted -
US 10294483
Eimeria tenella elongation factor-1 alpha recombinant immunogenic compositions which induce active protective immunity against avian coccidiosis
granted -
US 10286031
Method of manufacture of GnRH-containing gel
granted -
US 10286054
Attenuated EHEC and clostridial toxins TcdA and TcdB based vaccine for Clostridium difficil associated disease (CDAD)
granted -
US 10287297
Epoxyazulene derivatives useful for treating cancer and diabetes
granted -
US 10285935
Non-invasive method for direct delivery of therapeutics to the spinal cord in the treatment of spinal cord pathology
granted -
US 10287279
Inhibitors of human 12/15-lipoxygenase
granted -
US 10287350
Chimeric antigen receptors targeting CD-19
granted -
US 10287340
Anti-HIV domain antibodies and method of making and using same
granted -
US 10286064
Cationic lipid vaccine compositions and methods of use
granted -
US 10286050
Multi-epitope TARP peptide vaccine and uses thereof
granted -
US 10280307
Class of stable heptamethine cyanine fluorophores and biomedical applications thereof
granted
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources ยท Patent directory